TY - JOUR
T1 - Comparison of three commercial tools for metagenomic shotgun sequencing analysis
AU - Thoendel, Matthew
AU - Jeraldo, Patricio
AU - Greenwood-Quaintance, Kerryl E.
AU - Yao, Janet
AU - Chia, Nicholas
AU - Hanssen, Arlen D.
AU - Abdel, Matthew P.
AU - Patel, Robin
N1 - Funding Information:
Research reported in this publication was supported by the National Institutes of Health under award number R01 AR056647. N.C. is supported by R01 CA179243. R.P. reports grants from CD Diagnostics, BioFire, Curetis, Merck, Contrafect, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, EnBiotix, Contrafect, and The Medicines Company. R.P. is or has been a consultant to Curetis, Specific Technologies, Next Gen Diagnostics, Accelerate Diagnostics, Selux Dx, GenMark Diagnostics, PathoQuest, Heraeus Medical, and Qvella; relevant monies are paid to Mayo Clinic. In addition, R.P. has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an antibiofilm substance issued. R.P. receives travel reimbursement from the American Society for Microbiology (ASM) and the Infectious Diseases Society of America (IDSA) and an editor’s stipend from IDSA and honoraria from the National Board of Medical Examiners (NBME), Up-to-Date, and the Infectious Diseases Board Review Course. The content of this report is solely our responsibility and does not necessarily represent the official views of the National Institutes of Health.
Funding Information:
Research reported in this publication was supported by the National Institutes of Health under award number R01 AR056647. N.C. is supported by R01 CA179243. R.P. reports grants from CD Diagnostics, BioFire, Curetis, Merck, Contrafect, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, EnBiotix, Contrafect, and The Medicines Company. R.P. is or has been a consultant to Curetis, Specific Technologies, Next Gen Diagnostics, Accelerate Diagnostics, Selux Dx, GenMark Diagnostics, PathoQuest, Heraeus Medical, and Qvella; relevant monies are paid to Mayo Clinic. In addition, R.P. has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an antibiofilm substance issued. R.P. receives travel reimbursement from the American Society for Microbiology (ASM) and the Infectious Diseases Society of America (IDSA) and an editor?s stipend from IDSA and honoraria from the National Board of Medical Examiners (NBME), Up-to-Date, and the Infectious Diseases Board Review Course. The content of this report is solely our responsibility and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
Copyright © 2020 American Society for Microbiology. All Rights Reserved.
PY - 2020
Y1 - 2020
N2 - Metagenomic shotgun sequencing for the identification of pathogens is being increasingly utilized as a diagnostic method. Interpretation of large and complicated data sets is a significant challenge, for which multiple commercial tools have been developed. Three commercial metagenomic shotgun sequencing tools, CosmosID, One Codex, and IDbyDNA, were compared to determine whether they result in similar interpretations of the same sequencing data. We selected 24 diverse samples from a previously characterized data set derived from DNA extracted from biofilms dislodged from the surfaces of resected arthroplasties (sonicate fluid). Sequencing data sets were analyzed using the three commercial tools and compared to culture results and prior metagenomic analysis interpretation. Identical interpretations from all three tools occurred for 6 samples. The total number of species identified included 28 by CosmosID, 59 by One Codex, and 41 by IDbyDNA. All of the tools performed similarly in detecting those microorganisms identified by culture, including polymicrobial mixes. These data show that while all of the tools performed well overall, there were some differences, particularly in their predilection for identifying low-abundance or contaminant organisms as present.
AB - Metagenomic shotgun sequencing for the identification of pathogens is being increasingly utilized as a diagnostic method. Interpretation of large and complicated data sets is a significant challenge, for which multiple commercial tools have been developed. Three commercial metagenomic shotgun sequencing tools, CosmosID, One Codex, and IDbyDNA, were compared to determine whether they result in similar interpretations of the same sequencing data. We selected 24 diverse samples from a previously characterized data set derived from DNA extracted from biofilms dislodged from the surfaces of resected arthroplasties (sonicate fluid). Sequencing data sets were analyzed using the three commercial tools and compared to culture results and prior metagenomic analysis interpretation. Identical interpretations from all three tools occurred for 6 samples. The total number of species identified included 28 by CosmosID, 59 by One Codex, and 41 by IDbyDNA. All of the tools performed similarly in detecting those microorganisms identified by culture, including polymicrobial mixes. These data show that while all of the tools performed well overall, there were some differences, particularly in their predilection for identifying low-abundance or contaminant organisms as present.
KW - Diagnosis
KW - metagenomics
UR - http://www.scopus.com/inward/record.url?scp=85079896062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079896062&partnerID=8YFLogxK
U2 - 10.1128/JCM.00981-19
DO - 10.1128/JCM.00981-19
M3 - Article
C2 - 31826963
AN - SCOPUS:85079896062
SN - 0095-1137
VL - 58
JO - Journal of clinical microbiology
JF - Journal of clinical microbiology
IS - 3
M1 - e00981-19
ER -